Active, not recruitingPhase 1NCT06084481
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
Studying Adult hepatocellular carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- AbbVie
- Principal Investigator
- ABBVIE INC.AbbVie
- Intervention
- ABBV-400(drug)
- Enrollment
- 302 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2026
Study locations (30)
- City of Hope National Medical Center /ID# 258645, Duarte, California, United States
- Ucsf /Id# 257705, San Francisco, California, United States
- University of Colorado Cancer Center - Cancer Clinical Trials Office /ID# 255128, Aurora, Colorado, United States
- Sarah Cannon Research Institute at HealthONE - Denver /ID# 258926, Denver, Colorado, United States
- Florida Cancer Specialists /ID# 261569, Sarasota, Florida, United States
- Northwestern University Feinberg School of Medicine /ID# 257378, Chicago, Illinois, United States
- University of Chicago Medical Center /ID# 258197, Chicago, Illinois, United States
- START Midwest /ID# 256581, Grand Rapids, Michigan, United States
- Washington University-School of Medicine /ID# 257379, St Louis, Missouri, United States
- Memorial Sloan Kettering Cancer Center-Koch Center /ID# 255132, New York, New York, United States
- Duke Cancer Center /ID# 255129, Durham, North Carolina, United States
- Univ Hosp Cleveland /ID# 257706, Cleveland, Ohio, United States
- Lifespan Cancer Institute at Rhode Island Hospital /ID# 257693, Providence, Rhode Island, United States
- MUSC Hollings Cancer Center /ID# 257935, Charleston, South Carolina, United States
- Prisma Health /ID# 257697, Greenville, South Carolina, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06084481 on ClinicalTrials.govOther trials for Adult hepatocellular carcinoma
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONPHASE2NCT07441369Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases CancerFudan University
- RECRUITINGPHASE2NCT07175441Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular CarcinomaRiboscience, LLC.
- RECRUITINGPHASE2NCT07560488Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular CarcinomaTianjin Medical University Cancer Institute and Hospital
- RECRUITINGPHASE2NCT07010497A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Bevacizumab in Patients With Hepatocellular CarcinomaAsan Medical Center
- RECRUITINGPHASE1, PHASE2NCT07291076A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)Bristol-Myers Squibb
- RECRUITINGPHASE1, PHASE2NCT07500220Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCCBeijing Biotech
- RECRUITINGPHASE2NCT07413354Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular CarcinomaTongji Hospital
- RECRUITINGNANCT07365527Sonoporation and Tumor Microenvironment Response in Colorectal Liver MetastasesZealand University Hospital